Date of publication: May 23, 2018

News & Views

Preview of ERA-EDTA 2018: Hyperkalaemia

The 55th annual ERA-EDTA congress is fast approaching, providing a vital opportunity for the sharing of new data, discussion of best practice and collaboration of international colleagues. In Copenhagen this year there will also be a new e-campus area showcasing the educational materials available at, as well as a rare conditions corner, dedicated learning stations, internet access and refreshments. You can find out more about the new-look e-campus in our recent news article.

In order to best plan your visit, aside from visiting the e-campus, the COMPACT RENAL team have selected the relevant posters and presentations covering hyperkalaemia, outlined below.

Thursday, May 24th

On the opening day of the congress is a CME Course discussing the implementation of European Renal Best Practice guidelines, including a presentation by Stephen Walsh, UK called ‘Hyperkalaemia – the ERBP treatment algorithm through case vignettes’.

A second CME session of interest, ‘The challenge of decreasing cardiovascular mortality in CKD’ will be led by the EUropean REnal and CArdiovascular Medicine (EURECA-m) Working Group and include a talk on potassium management in patients with CKD and hypertension by Patrick Rossignol, France.

To obtain CME credits you must scan your ERA-EDTA membership badge as you enter the lecture hall.

Friday, May 25th

The industry symposium of interest on Friday is entitled ‘Controversies surrounding RAASi treatment and hyperkalaemia in cardio-renal patients’ sponsored by Vifor Fresenius Medical Care Renal Pharma. Led by Professor John Cunningham, UK, the speakers will cover the pathophysiology of recurrent hyperkalaemia, the importance of RAASi therapy and options for maintaining RAASi use whilst managing potassium. The session will also include use of a patient case study to allow the speakers to translate the clinical trial evidence into real-world practice.

At the end of Friday is the Free Communication session, ‘CKD risk and progression’, chaired by Ivan Rychlik, Czech Republic and Peter Stenvinkel, Sweden. The talk of interest by Fernando Caravaca-Fontan, Spain, reports a study of the relationship between hyperkalaemia and clinical outcomes such as mortality and hospitalisation in non-dialysis dependent patients [FO062].

Posters of interest on Friday include:

  • FP071 presents results of an open-label, Phase III trial of sodium zirconium cyclosilicate for the treatment of hyperkalaemia for up to 12 months
  • FP102 compares the effects of patiromer on serum potassium levels in hyperkalaemic patients with and without obesity using pooled data from three clinical trials

Several other posters cover the epidemiology of hyperkalaemia:

  • FP337 examines RAASi dosing patterns and association with hyperkalaemia in the UK
  • FP341 looks at quantifying the mortality risk associated with elevated potassium over time, as well as correcting for confounders
  • FP364 presents analysis of the management of recurrent hyperkalaemic events in patients across Europe, including active treatment and RAASi use
  • FP371 reports the incidence and recurrence of hyperkalaemia in CKD stage 3+ patients in the UK, and the increased length-of-stay and mortality following hospitalisation

Saturday, May 26th

Starting the day is the early morning symposium, ‘Challenges in CKD’, which will include a presentation entitled ‘Milestones in hyperkalemia therapy or just an innovation?’ by Ziad Massy, France.

The Free Communication symposium, ‘CKD Epidemiology’ contains two talks of interest:SaO023 evaluates the hypothesis that CKD progression adapts to provide tolerance of high levels of potassium; while SaO024 looks at the association between hyperkalaemia and use of mineralocorticoid receptor antagonists in the CKD population of Stockholm.

A lunchtime educational session, ‘Innovations in CKD: Can K+-Binders and HIF Stabilisers Improve Mr Andersen’s Life?’, is supported by an educational grant from AstraZeneca and tackles two persistent complications for CKD patients – hyperkalaemia and renal anaemia. Chaired by Biff Palmer, USA, candidates are invited to meet Mr Andersen, and discuss how new innovations might provide the best treatment, not only for Mr Andersen, but for all patients.

And finishing the day in the Free Communication session ‘Outcome in dialysis’ is a presentation of a meta-analysis exploring the association of serum potassium with mortality in both non-dialysis and dialysis patients.[SaO068]

Posters of interest on Saturday includeSP421, which takes a retrospective look at the effects of sodium zirconium cyclosilicate on CKD patients with and without diabetesin a 12-month, open label trial, while further epidemiological studies also feature on Saturday:

  • SP299 reports healthcare utilisation and costs associated with hyperkalaemia in CKD
  • SP307 investigated any change in serum potassium levels in relation to RAASi and/or beta-blocker use in patients with end-stage renal disease
  • SP324 looks at the rates of hyperkalaemia in patients receiving RAASi therapy in the general population of England (those with and without CKD)

Sunday, May 27th

Part of the Free Communication session ‘Nutrition in CKD’, on Sunday morning is a talk by Rik H. G. Olde Engberink, Netherlands, comparing the use of a single 24-hr urine sample with multiple samples in assessing long-term potassium intake and associated renal and cardiovascular risk. [SuO002]

We wish you a safe journey to Copenhagen, and look forward to reporting back on all the key presentations here at

Leave a Reply


You are about to leave

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel